Success Metrics

Clinical Success Rate

100.0%

Based on 7 completed trials

Completion Rate

100%(7/7)

Active Trials

1(9%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_4

55%

Ph phase_1

27%

Ph phase_2

Ph phase_3

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution11 total trials

Phase 1Safety & dosage

3(27.3%)

Phase 2Efficacy & side effects

1(9.1%)

Phase 3Large-scale testing

1(9.1%)

Phase 4Post-market surveillance

6(54.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(7)

Other(2)

Detailed Status

Completed7

unknown2

Not yet recruiting1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 13 (27.3%)

Phase 21 (9.1%)

Phase 31 (9.1%)

Phase 46 (54.5%)

Trials by Status

not_yet_recruiting19%

unknown218%

completed764%

recruiting19%

Recent Activity

1 active trials

Showing 5 of 11

recruitingphase_4

Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations

NCT07354269

completedphase_4

Booster Dose of sIPV Co-administered With MMR and HepA-I.

NCT06442449

completedphase_3

Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)

NCT07297186

not_yet_recruitingphase_4

Study of Concomitant Administration of the sIPV and DTaP or MMR

NCT06920069

completedphase_4

Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers

NCT06346834

View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials

NCT07354269Phase 4

Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations

Recruiting

NCT06442449Phase 4

Booster Dose of sIPV Co-administered With MMR and HepA-I.

Completed

NCT07297186Phase 3

Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)

Completed

NCT06920069Phase 4

Study of Concomitant Administration of the sIPV and DTaP or MMR

Not Yet Recruiting

NCT06346834Phase 4

Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufacturers

Completed

NCT03566940Phase 2

A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule

Completed

NCT03032588Phase 1

A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults

Completed

NCT04638985Phase 4

Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR

Unknown

NCT04636827Phase 4

Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA

Unknown

NCT04264546Phase 1

Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib)

Completed

NCT04264598Phase 1

Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine